Short answer
Sanara MedTech Inc. (SMTI) filed its Q1 2026 10-Q quarterly report on May 12, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $28M (up 18.6% year over year) with net income of $458,957.
Q1 2026 key financials · XBRL
- Revenue
- $28M
- +18.6% YoY
- Net income
- $458,957
- +113.0% YoY
- Operating margin
- 9.5%
- Gross margin
- 93.1%
- EPS (diluted)
- $0.05
- +112.2% YoY
Source: XBRL data from the Sanara MedTech Inc. (SMTI) Q1 2026 10-Q on SEC EDGAR. USD.
Sanara MedTech Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q1 revenue $27.8M vs $23.4M, up 19% YoY
- Soft tissue repair $24.9M, up 21%; bone fusion $2.9M, down 2%
- Gross margin 93% vs 92%; net income $0.4M vs $0.6M loss
- Cash $13.6M vs $16.6M at December 31, 2025; THP wind-down cash outlay $0.4M
- Outlook: cash expected sufficient for at least 12 months; THP wind-down spend not material thereafter
Risk Factors
- No material risk-factor changes provided from the December 31, 2025 Form 10-K
- No new regulatory, legal, or compliance risk identified in the supplied section
- No new operational, competitive, or market risk identified in the supplied section
- No new liquidity, debt, currency, or concentration risk identified in the supplied section
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Sanara MedTech Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.